[Administration of intrapartum erythromycin for the interruption of the vertical transmission of Ureaplasma urealyticum and its possible relation to the development of bronchopulmonary dysplasia in neonates with less than 32 weeks gestation. Multicenter study].
Salcedo Abizanda
S
S
Servicio de Neonatología, Hospital Universitario Materno-infantil Valle de Hebrón Ciudad Sanitaria Valle de Hebrón, Barcelona.
Cabero Roura
L
L
Andreu Domingo
A
A
Lucaya Layret
J
J
Perapoch López
J
J
Casellas Caro
M
M
Fernández Pérez
F
F
Campins Martí
M
M
Torán Fuentes
N
N
Peguero Monforte
G
G
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001997:Bronchopulmonary Dysplasia / Q000209:etiology*; D004917:Erythromycin / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D018445:Infectious Disease Transmission, Vertical; D016869:Ureaplasma Infections / Q000150:complications / Q000517:prevention & control* / Q000635:transmission; D016990:Ureaplasma urealyticum
D000900:Anti-Bacterial Agents; D004917:Erythromycin